Lucentis (Treat and extend) — Competitive Intelligence Brief

Lucentis (Treat and extend) (Lucentis (Treat and extend)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: VEGF inhibitor (monoclonal antibody fragment). Area: Ophthalmology.

marketed VEGF inhibitor (monoclonal antibody fragment) VEGF-A Ophthalmology Small molecule

Target snapshot

Lucentis (Treat and extend) (Lucentis (Treat and extend)) — Retinal Consultants of Arizona. Lucentis (ranibizumab) blocks vascular endothelial growth factor (VEGF) to reduce abnormal blood vessel growth and leakage in the retina.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Lucentis (Treat and extend) TARGET	Lucentis (Treat and extend)	Retinal Consultants of Arizona	marketed	VEGF inhibitor (monoclonal antibody fragment)	VEGF-A
ranibizumab PRN	ranibizumab PRN	Seoul National University Hospital	marketed	VEGF-A inhibitor monoclonal antibody fragment	VEGF-A (Vascular Endothelial Growth Factor A)
intravitreal ranibizumab injections	intravitreal ranibizumab injections	Hospital Regional de São José - Dr. Homero de Miranda Gomes	marketed	VEGF inhibitor (monoclonal antibody fragment)	VEGF-A (Vascular Endothelial Growth Factor A)
Aflibercept and ranibizumab	Aflibercept and ranibizumab	Instituto de Olhos de Goiania	marketed	Anti-VEGF agent	VEGF-A (and VEGF-B for aflibercept)
Ranibizumab and Aflibercept	Ranibizumab and Aflibercept	Instituto de Olhos de Goiania	marketed	Anti-VEGF agent	VEGF-A (vascular endothelial growth factor-A)
Syfovre™	Syfovre™	Hoffmann-La Roche	marketed	Anti-VEGF aptamer	VEGF-A
Intravitreal Ranibizumabe	Intravitreal Ranibizumabe	University of Sao Paulo	marketed	VEGF-A inhibitor; monoclonal antibody fragment	VEGF-A (Vascular Endothelial Growth Factor A)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (VEGF inhibitor (monoclonal antibody fragment) class)

1. Hospital Regional de São José - Dr. Homero de Miranda Gomes · 1 drug in this class
2. Jaeb Center for Health Research · 1 drug in this class
3. Retinal Consultants of Arizona · 1 drug in this class
4. University Hospital Muenster · 1 drug in this class